Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nyxoah ( (NYXH) ) has shared an update.
On May 23, 2025, Nyxoah SA announced the issuance of new shares, updating its total share capital to EUR 6,430,026.16 and the total number of voting rights to 37,429,265. This move reflects the company’s ongoing efforts to strengthen its financial position and potentially expand its operations. The update in share capital and voting rights is significant for stakeholders as it indicates a strategic step in Nyxoah’s growth trajectory, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR19.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA operates in the medical technology industry, focusing on the development and commercialization of innovative solutions for the treatment of sleep-disordered breathing conditions. The company is known for its minimally invasive neurostimulation therapy aimed at addressing Obstructive Sleep Apnea (OSA).
Average Trading Volume: 88,474
Current Market Cap: €239.3M
See more data about NYXH stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue